MARKET

BIOC

BIOC

Biocept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3200
-0.0166
-4.93%
After Hours: 0.3087 -0.0113 -3.53% 18:13 01/24 EST
OPEN
0.3333
PREV CLOSE
0.3366
HIGH
0.3365
LOW
0.3158
VOLUME
2.83M
TURNOVER
--
52 WEEK HIGH
2.500
52 WEEK LOW
0.2275
MARKET CAP
15.24M
P/E (TTM)
-0.1200
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BIOC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BIOC News

  • 23andMe to cut 14% of staff as business slows
  • seekingalpha.2d ago
  • Biocept validates liquid biopsy tests in cerebrospinal fluid; shares up 19%
  • seekingalpha.01/14 19:52
  • Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal Fluid
  • PR Newswire.01/14 13:05
  • How Does Investing In Biocept, Inc. (NASDAQ:BIOC) Impact The Volatility Of Your Portfolio?
  • Simply Wall St..01/12 13:22

More

Industry

Medical Equipment, Supplies & Distribution
-0.74%
Healthcare Equipment & Supplies
-0.90%

Hot Stocks

Name
Price
%Change

About BIOC

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
More

Webull offers Biocept Inc (BIOC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.